← All trials
NCT05510856
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2022
- Primary completion
- Sep 30, 2023
- Completion date
- Sep 30, 2024
- First posted
- Aug 22, 2022
- Last posted
- Oct 20, 2022
- Enrollment
- 90
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Tanta UniversityLead sponsor
- Tanta UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.